Enfermedad intersticial pulmonar secundaria a infección por SARS-CoV-2 en paciente con artritis reumatoide
Palabras clave:
COVID-19, infecciones por coronavirus, artritis reumatoide, enfermedades pulmonares intersticiales
Resumen
La presentación clínica de COVID-19 es heterogénea, desde casos asintomáticos, hasta síndrome de dificultad respiratoria aguda y muerte. La enfermedad grave puede ocurrir en pacientes con comorbilidades, incluidos pacientes con enfermedades reumáticas sistémicas. El impacto de la artritis reumatoide en pacientes que cursan con COVID-19 aún no está claro.
Presentamos el caso de un paciente con antecedente de AR, quien cursó con COVID-19, y reingresó con insuficiencia respiratoria aguda y hallazgos tomográficos de enfermedad intersticial pulmonar de rápida evolución.
Citas
1. Tenes JA, Laorden D, Cabanillas JJ, Prados C. Enfermedad intersticial pulmonar. Medicine. 2018; 12(67): 3909-16
2. Kalchiem-Dekel Or, Galvin JR, Burke AP, Atamas SP, Todd NW. Intersticial lung disease and pulmonary fibrosis: A practical approach for general medicine physicians with focus on the medical history. J Clin Med. 2018; 7(12): 476. doi: 10.3390/jcm7120476
3. Kelly CA, Saravanan V, Nisar M, Arthanari S, Woodhead FA, Price-Forbes AN, et al. Rheumatoid arthritis-related interstitial lung disease: Associations, prognostic factors and physiological and radiological characteristics-- a large multicentre UK study. Rheumatology (Oxford). 2014; 53(9): 1676-82. doi: 10.1093/rheumatology/keu165
4. Balbir-Gurman A, Guralnik L, Yigla M, Braun-Moscovici Y, Hardak E. Imaging aspects of intersticial lung disease in patients with rheumatoid arthritis: Literature review. Autoimmun Rev. 2018; 17(2): 87-93. doi: 10.1016/j.autrev.2017.09.013
5. Diaz Santos G, Matiz CE, Pinzón B. Presentación de la enfermedad pulmonar intersticial durante la pandemia de COVID-19. Rev Colom Neum. 2021; 32(1):78-86. doi:10.30789/rcneumologia.v32.n1.2020.514
6. Blanco JR, Cobos-Ceballos MJ, Navarro F, Sanjoaquin I, Arnaiz de Las Revillas F, Bernal E, et al. Pulmonary long-term consequences of COVID-19 infections after hospital discharge. Clin Microbiol Infect. 2021; 27(6):892-896. doi 10.1016/j.cmi.2021.02.019
7. Udwadia ZF, Koul PA, Richeldi L. Post-COVID lung fibrosis: The tsunami that will follow the earthquake. Lung India. 2021; 38(Suppl):41-7. doi: 10.4103/lungindia.lungindia_818_20
8. Salehi S, Abedi A, Balakrishnan S, Gholamrezanezhad A. Coronavirus disease 2019 (COVID-19): A systematic review of imaging findings in 919 patients. AJR Am J Roentgenol. 2020; 215(1): 87-93. doi: 10.2214/AJR.20.23034
9. Wang Ch, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet. 2020; 395(1023): 470-3. doi: 10.1016/S0140-6736(20)30185-9
10. D'Silva KM, Wallace ZS. COVID-19 and rheumatoid arthritis. Curr Opin Rheumatol. 2021; 33(3):255-61. doi: 10.1097/BOR.0000000000000786
11. Fragoulis GE, Nikiphorou E, Larsen J, Korsten P, Conway R. Methotrexate-Associated pneumonitis and rheumatoid arthritis-interstitial lung disease: Current concepts for the diagnosis and treatment. Front Med (Lausanne). 2019; 6:238 doi: 10.3389/fmed.2019.00238
2. Kalchiem-Dekel Or, Galvin JR, Burke AP, Atamas SP, Todd NW. Intersticial lung disease and pulmonary fibrosis: A practical approach for general medicine physicians with focus on the medical history. J Clin Med. 2018; 7(12): 476. doi: 10.3390/jcm7120476
3. Kelly CA, Saravanan V, Nisar M, Arthanari S, Woodhead FA, Price-Forbes AN, et al. Rheumatoid arthritis-related interstitial lung disease: Associations, prognostic factors and physiological and radiological characteristics-- a large multicentre UK study. Rheumatology (Oxford). 2014; 53(9): 1676-82. doi: 10.1093/rheumatology/keu165
4. Balbir-Gurman A, Guralnik L, Yigla M, Braun-Moscovici Y, Hardak E. Imaging aspects of intersticial lung disease in patients with rheumatoid arthritis: Literature review. Autoimmun Rev. 2018; 17(2): 87-93. doi: 10.1016/j.autrev.2017.09.013
5. Diaz Santos G, Matiz CE, Pinzón B. Presentación de la enfermedad pulmonar intersticial durante la pandemia de COVID-19. Rev Colom Neum. 2021; 32(1):78-86. doi:10.30789/rcneumologia.v32.n1.2020.514
6. Blanco JR, Cobos-Ceballos MJ, Navarro F, Sanjoaquin I, Arnaiz de Las Revillas F, Bernal E, et al. Pulmonary long-term consequences of COVID-19 infections after hospital discharge. Clin Microbiol Infect. 2021; 27(6):892-896. doi 10.1016/j.cmi.2021.02.019
7. Udwadia ZF, Koul PA, Richeldi L. Post-COVID lung fibrosis: The tsunami that will follow the earthquake. Lung India. 2021; 38(Suppl):41-7. doi: 10.4103/lungindia.lungindia_818_20
8. Salehi S, Abedi A, Balakrishnan S, Gholamrezanezhad A. Coronavirus disease 2019 (COVID-19): A systematic review of imaging findings in 919 patients. AJR Am J Roentgenol. 2020; 215(1): 87-93. doi: 10.2214/AJR.20.23034
9. Wang Ch, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet. 2020; 395(1023): 470-3. doi: 10.1016/S0140-6736(20)30185-9
10. D'Silva KM, Wallace ZS. COVID-19 and rheumatoid arthritis. Curr Opin Rheumatol. 2021; 33(3):255-61. doi: 10.1097/BOR.0000000000000786
11. Fragoulis GE, Nikiphorou E, Larsen J, Korsten P, Conway R. Methotrexate-Associated pneumonitis and rheumatoid arthritis-interstitial lung disease: Current concepts for the diagnosis and treatment. Front Med (Lausanne). 2019; 6:238 doi: 10.3389/fmed.2019.00238
